Arkolith/Insider Trading/EBS/Form 4

Lindahl Richard S

EVP, Chief Financial OfficerEmergent BioSolutions Inc. (EBS) · full profile →Form 4 · filed Mar 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 25, 2026Expiration(H)20K—$00
May 7, 2025Expiration(H)20K—$00

Transaction Codes

H
See SEC Form 4 code table

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001196632-26-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML